EGW

Core & Main Signs Agreement to Acquire EGW Utilities Inc.

Retrieved on: 
Monday, March 25, 2024
Transport, Logistics, Supply Chain Management, CNM, Acquisition, Knowledge, EGW, Management

Core & Main Inc. (NYSE: CNM), a leader in advancing reliable infrastructure with local service, nationwide, has entered into a definitive agreement to acquire substantially all of the assets of EGW Utilities, Inc. (EGW), a distributor of quality products and services to underground utility contractors and municipalities, based in Texas.

Key Points: 
  • Core & Main Inc. (NYSE: CNM), a leader in advancing reliable infrastructure with local service, nationwide, has entered into a definitive agreement to acquire substantially all of the assets of EGW Utilities, Inc. (EGW), a distributor of quality products and services to underground utility contractors and municipalities, based in Texas.
  • "With the acquisition of EGW, we are excited to expand our product offering and service capabilities in the underground utility industry," said Steve LeClair, chairman and CEO of Core & Main.
  • We look forward to welcoming the EGW team into the Core & Main family."
  • These are values we share with Core & Main, and that played a big role in our decision to join forces.

Expro and Frank’s Complete Merger, Creating a New Full-Cycle Energy Services Leader

Retrieved on: 
Friday, October 1, 2021
Commercial Building & Real Estate, Energy, Construction & Property, Oil, Gas, Nature, Securities Act of 1933, Perception, Public expenditure, New, Solution, Board of directors, U.S. Securities and Exchange Commission, Multimedia, FI, Axa XL, Carbon, Global warming potential, Hess Corporation, LinkedIn, EGW, Board, Carrier oil, Senior, CEO, Group, Royal Dutch Shell, Company, Growth, National, Entrepreneurship, Risk, Dedication, COVID-19, Forward-looking statement, Securities Exchange Act of 1934, Pacific Ocean, NYSE, Time, SEC, Oil, Risk management, Retail, Renewable energy, Management

This is an exciting day for Expro and Franks as we bring our companies together to create a new global leader with the breadth of capabilities and expertise across the well lifecycle to better support customers, said Mike Jardon, Chief Executive Officer of Expro.

Key Points: 
  • This is an exciting day for Expro and Franks as we bring our companies together to create a new global leader with the breadth of capabilities and expertise across the well lifecycle to better support customers, said Mike Jardon, Chief Executive Officer of Expro.
  • I would like to thank everyone at Expro and Franks for their great work in completing the transaction, planning for a successful integration, and positioning the combined company for long-term success.
  • Expro is governed by an experienced Board of Directors led by Mike Kearney as Board Chairman.
  • For more information, please visit: expro.com and connect with Expro on Twitter @ExproGroup and LinkedIn @Expro.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

Retrieved on: 
Thursday, March 4, 2021
Medical specialties, Infectious causes of cancer, EGW, Wart, Genital wart, Microbiology, Clinical medicine

Verrica announced positive topline results from its Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).

Key Points: 
  • Verrica announced positive topline results from its Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verrica reported a net loss of $13.0million for the fourth quarter of 2020, compared to a $7.6 million net loss for the same period in 2019.
  • Research and development expenses were $2.3million in the fourth quarter of 2020, compared to $4.0 million for the same period in 2019.
  • General and administrative expenses were $9.8million in the fourth quarter of 2020, compared to $4.0 million for the same period in 2019.

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Retrieved on: 
Tuesday, January 19, 2021
Medical specialties, Virology, Clinical medicine, Infectious causes of cancer, EGW, Molluscum contagiosum, Wart, Genital wart, Dermatology, Imiquimod, Koebner phenomenon

The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.

Key Points: 
  • The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
  • VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.
  • Data were also presented from Verricas Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

Retrieved on: 
Tuesday, November 10, 2020
Medical specialties, Infectious causes of cancer, EGW, Microbiology, Wart, Genital wart, VP-102, Clinical medicine

Safety results from Part A supported use of VP-102 for both 6-hour and 24-hour treatment exposures in Part B.

Key Points: 
  • Safety results from Part A supported use of VP-102 for both 6-hour and 24-hour treatment exposures in Part B.
  • Topline analyses included data from the assessment of EGW at study visits at days 21, 42, 63, and 84.
  • In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.